Repare Therapeutics (RPTX) AI Stock Analysis

• Market Cap: $112.08M
• Dividend Yield: N/A
• Average Volume (3M): 138.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.92
• Revenue Growth: -82.16%
• EPS Growth: 14.58%
• Country: US
• Employees: 129
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.08
• Shares Outstanding: 43,108,360
• 10 Day Avg. Volume: 221,679
• 30 Day Avg. Volume: 138,921
• PEG Ratio: 0.06
• Price to Book (P/B): 0.37
• Price to Sales (P/S): 1.04
• P/FCF Ratio: -0.73
• Enterprise Value/Market Cap: -0.44
• Enterprise Value/Revenue: -4.14
• Enterprise Value/Gross Profit: -4.81
• Enterprise Value/Ebitda: 0.68
• 1Y Price Target: $3.00
• Price Target Upside: 15.38% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $2.50 ▼(-3.85% Downside)

The score is held back primarily by weak financial performance (deep losses and ongoing cash burn), partially offset by a strong balance sheet and positive corporate developments (asset sale boosting cash and early clinical updates). Technicals are constructive with a strong trend, but near-overbought signals and limited valuation support due to negative earnings temper the upside.

Positive Factors

Low Leverage / Strong Balance Sheet

Very low debt and minimal leverage provide durable financial flexibility for a development-stage biotech. This lowers insolvency risk, supports continued R&D spending or selective partnering without immediate dilution, and extends runway versus highly leveraged peers.

Asset Sale Boosts Liquidity

The RP-3467 sale is a structural cash infusion that meaningfully improves near-term liquidity and reduces reliance on equity markets. It strengthens the company’s ability to fund core programs, negotiate partnerships, and support execution through the upcoming acquisition process.

Positive Early Clinical Readout

Demonstrated safety and early antitumor activity in Phase 1 materially de-risks RP-1664 relative to preclinical assets. Durable clinical signals can attract partners, enable non-dilutive deals, and enhance the company’s long-term pipeline value even if commercial execution remains future-dated.

Negative Factors

Persistent Cash Burn

Materially negative operating and free cash flow indicate ongoing dependence on external funding to sustain operations. Over a multi-month horizon this constrains strategic flexibility, increases dilution risk if additional capital is required, and pressures program timelines.

Deep and Recurring Losses

Sustained large operating losses and negative returns on equity show the company is consuming capital rather than compounding it. Until revenues from partnered products or successful commercialization arrive, persistent losses will limit ability to self-fund growth and strain shareholder returns.

Senior Scientific Leadership Turnover

A CSO departure during active M&A raises execution risk for clinical programs and scientific continuity. Transition costs, potential knowledge gaps, and distraction from integration activities can slow development decisions and complicate handoff of program oversight post-acquisition.

Repare Therapeutics Business Overview & Revenue Model

Company Description

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

How the Company Makes Money

Repare Therapeutics generates revenue primarily through the advancement of its drug candidates in clinical trials, leading to potential partnerships and licensing agreements with larger pharmaceutical companies. Key revenue streams include milestone payments from collaborators as drug candidates progress through development stages, royalties from sales of partnered products, and potential upfront payments from strategic alliances. The company's focus on synthetic lethality and precision oncology attracts interest from major players in the pharmaceutical industry, enhancing its potential for lucrative partnerships and collaborations that contribute to its earnings.

Repare Therapeutics Financial Statement Overview

Summary

Repare Therapeutics faces significant financial challenges with consistent losses and revenue volatility. Despite these issues, the balance sheet shows relative stability with a strong cash position and low leverage, providing some buffer for future operations.

Income Statement

Repare Therapeutics has shown significant revenue volatility over the years, with revenue dropping to zero in the most recent period from $51.13 million the previous year and $131.83 million two years prior. The company has consistently incurred operating losses, and negative net income, indicating ongoing profitability challenges. The EBIT and EBITDA margins are negative, reflecting operational inefficiencies. However, the company showed a brief revenue surge in 2022, which might indicate potential for recovery.

Balance Sheet

The company maintains a strong equity base relative to its liabilities, reflected in a low Debt-to-Equity ratio, which suggests stability. Despite consistent net losses, Repare's cash position remains robust, indicating prudent cash management. However, the Return on Equity is negative due to sustained net losses, which impacts overall shareholder returns negatively. The equity ratio has shown some decline but remains relatively healthy.

Cash Flow

Repare Therapeutics has faced challenges with negative free cash flow, although the cash flow from investing activities has been positive, largely due to asset management. The operating cash flow remains negative, indicating that the company is not generating enough cash from core operations to cover expenses. However, the company has managed to sustain cash reserves, which provides liquidity to continue operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.87M	53.48M	51.13M	131.83M	7.60M	135.00K
Gross Profit	10.23M	40.10M	37.89M	15.11M	-80.25M	-38.64M
EBITDA	-71.98M	-90.22M	-114.27M	-17.82M	-107.19M	-53.41M
Net Income	-72.20M	-84.69M	-93.80M	-29.05M	-106.91M	-53.42M
Balance Sheet
Total Assets	126.75M	176.51M	253.90M	364.07M	368.71M	357.09M
Cash, Cash Equivalents and Short-Term Investments	112.60M	152.79M	223.63M	343.94M	341.87M	333.71M
Total Debt	342.00K	1.93M	3.41M	5.43M	7.31M	4.00M
Total Liabilities	11.62M	25.38M	41.82M	84.56M	80.29M	70.26M
Stockholders Equity	115.13M	151.13M	212.08M	279.52M	288.42M	286.83M
Cash Flow
Free Cash Flow	-70.15M	-76.44M	-129.10M	-280.00K	-87.49M	-8.32M
Operating Cash Flow	-70.15M	-76.44M	-127.16M	322.00K	-85.80M	-6.08M
Investing Cash Flow	62.33M	49.47M	78.04M	-175.78M	-1.68M	-9.76M
Financing Cash Flow	110.00K	542.00K	842.00K	880.00K	95.56M	247.84M

Repare Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPTX, the sentiment is Positive. The current price of 2.6 is above the 20-day moving average (MA) of 2.45, above the 50-day MA of 2.19, and above the 200-day MA of 1.68, indicating a bullish trend. The MACD of 0.12 indicates Positive momentum. The RSI at 71.20 is Negative, neither overbought nor oversold. The STOCH value of 52.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RPTX.

Repare Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	58 Neutral	$112.08M	-1.53	-49.78%	―	-82.16%	14.58%
PRLD	56 Neutral	$127.95M	-1.40	-103.99%	―	250.00%	15.15%
LTRN	52 Neutral	$39.59M	-2.02	-104.58%	―	―	1.18%
UNCY	52 Neutral	$142.06M	-2.03	-102.47%	―	―	66.05%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PLRX	42 Neutral	$80.50M	-0.46	-64.27%	―	―	14.19%
GBIO	39 Underperform	$38.07M	-0.60	-80.81%	―	-17.82%	57.32%

Repare Therapeutics Corporate Events

Repare Therapeutics Sells RP-3467 Program to Gilead

On December 23, 2025, Repare Therapeutics entered into an asset purchase agreement under which Gilead Sciences acquired all assets related to RP-3467, its Polθ ATPase inhibitor program for advanced solid tumors, for up to $30 million in cash, including $22–25 million in near-term payments and a further $5 million contingent on completion of technology transfer, while assuming specified related liabilities but leaving Repare’s other programs and core assets untouched. The transaction, announced publicly on December 24, 2025, follows New York University’s consent to assign its RP-3467 license to Gilead in exchange for a one-time $250,000 payment and represents Repare’s third and largest portfolio deal of 2025, significantly boosting its cash balance ahead of a previously announced acquisition by XenoTherapeutics and raising the company’s estimate of the cash consideration payable to shareholders at closing of that arrangement to about US$2.20 per share.

The most recent analyst rating on (RPTX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.

Repare Therapeutics announces CSO resignation and transition plan

On December 18, 2025, Repare Therapeutics announced that Chief Scientific Officer Michael Zinda, Ph.D., had resigned effective December 31, 2025, and entered into a separation agreement that provides nine months of salary, a retention payment, a 2025 target bonus, extended COBRA health coverage, accelerated vesting of certain equity awards, and an extended exercise window for vested stock options, alongside a three-month consulting arrangement at an hourly rate. The agreement also outlines enhanced change-in-control separation benefits that would replace the standard package if the planned acquisition of Repare by XenoTherapeutics or another qualifying change in control occurs on or shortly after his departure, underscoring both the company’s ongoing M&A process and the effort to manage executive transition and retention as shareholders prepare to vote on the Xeno deal at a special meeting on January 16, 2026.

The most recent analyst rating on (RPTX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.

Repare Therapeutics Announces Acquisition by XenoTherapeutics

Repare Therapeutics Inc. has entered into an Arrangement Agreement with XenoTherapeutics, Inc., wherein Xeno’s subsidiary will acquire all outstanding common shares of Repare. Shareholders will receive a cash payment per share and a contingent value right for potential future payments. The transaction, deemed fair and in the best interest of the company by its board, requires shareholder and court approvals and is subject to customary closing conditions.

The most recent analyst rating on (RPTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.

Repare Therapeutics Unveils Phase 1 LIONS Trial Data

On October 22, 2025, Repare Therapeutics announced the availability of an abstract related to their Phase 1 LIONS trial of RP-1664. This preliminary data, showcasing the safety and antitumor activity of RP-1664 in advanced solid tumors, will be presented at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

The most recent analyst rating on (RPTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page.